Total Funding
45
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
112066
Sierra Oncology is a clinical-stage drug development company that advances targeted therapeutics for the treatment of cancer patients.
Acquired by 
GlaxoSmithKline
Sukhi Jagpal: CFO- Jeffrey H. Cooper: Member of the Board of DirectorsPast Role: BioMarin Pharmaceutical, Senior Vice President and Chief Financial Officer
About the Company
Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. The company harnesses its deep scientific expertise to identify compounds that target the root cause of disease. Sierra Oncology's team takes an evidence-based approach to understand the limitations of current
treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
Women Founded
